Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Oslo University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 03, 2023
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Oslo University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 06, 2022
Lead Product(s) : Apricoxib,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Innovation Norway
Deal Size : $0.9 million
Deal Type : Funding
Innovation Norway Awards NOK 8.2 mn Grant to Targovax for Development of TG Mutant RAS Vaccine
Details : With the support from Innovation Norway, Targovax has move the TG program forward faster and more broadly, and thus bring benefit to a patient group with poor prognosis and few available treatment options.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 01, 2022
Lead Product(s) : Apricoxib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Innovation Norway
Deal Size : $0.9 million
Deal Type : Funding
Details : Undisclosed
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
September 30, 2022
Lead Product(s) : Apricoxib,QS-21 Stimulon
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Agenus
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 03, 2022
Lead Product(s) : Apricoxib,QS-21 Stimulon
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Agenus
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Targovax’s ONCOS-102 Mesothelioma 24-month Data Shows Class-leading Median Overall Survival
Details : The study is an open-label, exploratory phase 1/2 trial adding ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin) in first- and second- (or later) line MPM to assess safety, immune activation and clinical efficacy compared with SoC alone.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ONCOS-102,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Targovax Granted European Patent for ONCOS-102 in Combination with Chemotherapy
Details : The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma. ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune sys...
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
September 24, 2021
Lead Product(s) : ONCOS-102,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ONCOS-102,Cyclophosphamide,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Grants Fast Track Status To Targovax ONCOS-102 to Treat Refractory Advanced Melanoma
Details : The US FDA has granted Fast Track designation to ONCOS-102 based on the current pre-clinical and clinical data package, including mechanistic evidence showing an association between ONCOS-102-induced immune activation and tumor responses.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
June 24, 2021
Lead Product(s) : ONCOS-102,Cyclophosphamide,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Targovax Releases Presentations of ONCOS-102 Mesothelioma 24-Month Data
Details : ONCOS-102, an immune activators used in combination with Standard of Care (SoC) chemotherapy in patients with malignant pleural mesothelioma clearly shown tumor responses and survival outcomes.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
June 14, 2021
Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : IOVaxis Therapeutics
Deal Size : $3.0 million
Deal Type : Licensing Agreement
Details : Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 01, 2021
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : IOVaxis Therapeutics
Deal Size : $3.0 million
Deal Type : Licensing Agreement